UPDATE: PTC Therapeutics (PTCT) Initiated Neutral at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $62.62 -0.48%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
(Updated - October 27, 2020 5:00 PM EDT)
UBS analyst Colin Bristow started PTC Therapeutics (NASDAQ: PTCT) at Neutral, PT $55.00
You May Also Be Interested In
- PTC Therapeutics (PTCT) PT Lowered to $106 at Raymond James
- Truist Securities Starts PTC Therapeutics (PTCT) at Hold
- Wolfe Research Starts The TJX Companies (TJX) at Peerperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
